Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer
2023-505172-29-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of fianlimab and cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Pathological complete response. Planned start Apr 2025; status: authorised.
02
Drugs
fianlimabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505172-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505172-29-00.